Copper-Based Nanozymes for Tumor Therapy: Structural Design and Combination Strategies.
Copper-based nanozymes (CuNZs), a unique class of functional nanomaterials, have gradually become an important research direction in cancer therapy due to their unique structure and tunable catalytic
APA
Sun Z, Shao M, Qiu L (2026). Copper-Based Nanozymes for Tumor Therapy: Structural Design and Combination Strategies.. ACS applied materials & interfaces, 18(4), 6373-6396. https://doi.org/10.1021/acsami.5c22067
MLA
Sun Z, et al.. "Copper-Based Nanozymes for Tumor Therapy: Structural Design and Combination Strategies.." ACS applied materials & interfaces, vol. 18, no. 4, 2026, pp. 6373-6396.
PMID
41568596
Abstract
Copper-based nanozymes (CuNZs), a unique class of functional nanomaterials, have gradually become an important research direction in cancer therapy due to their unique structure and tunable catalytic properties in redox reactions. CuNZs can mimic diverse nature enzymes, such as oxidase, peroxidase, superoxide dismutase, and catalase, which enables them to efficiently regulate the generation of ROS in the tumor microenvironment (TME), thereby showing significant therapeutic potential in inhibiting tumor progression. This review summarizes the various enzymatic activities of CuNZs and their applications in cancer treatment, exploring the influence of factors such as size, morphology, valence state, and surface modification on their catalytic performance. Optimizing the design and regulation of CuNZs will help improve their efficacy and selectivity in cancer therapy, overcoming resistance and side effects associated with traditional treatments. In the future, the application of CuNZs in multimodal combination therapy may offer more effective and precise solutions for cancer treatment.
MeSH Terms
Humans; Copper; Neoplasms; Antineoplastic Agents; Tumor Microenvironment; Animals; Nanostructures; Catalysis; Reactive Oxygen Species
같은 제1저자의 인용 많은 논문 (5)
- Dormancy and Recurrence in Breast Cancer Bone Metastasis: From Mechanisms to Clinical Translation.
- Comprehensive pan-cancer analysis and experimental verification of the roles of SCP2 in colon adenocarcinoma.
- Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs.
- Analysis of external dose rate attenuation and its related factors in differentiated thyroid carcinoma patients following I-131 therapy.
- Constitutive AMPK activation prevents hepatocellular carcinoma development through inhibition of HNF4α activity.